When you begin treatment with Actemra (tocilizumab), understanding how it’s given and how often is essential. Every detail, from the delivery method to the timing of your doses, can shape how well your treatment works.
You have two main options, and each method has different requirements, different schedules, and different steps you’ll need to follow carefully.
In this guide, we’ll walk through what a typical Actemra dosing schedule looks like, how it is delivered, and how you can stay consistent with your therapy.
Actemra Administration Routes
You can receive Actemra in two ways:
Intravenous (IV) Infusion
Actemra can be given directly into your bloodstream through an IV line over a set period of time, usually in a clinic or hospital. The medication needs to be diluted and will be given by a healthcare professional.
Subcutaneous (SC) Injection
Actemra can also be injected under your skin. After you are properly trained, you may be able to give these injections to yourself at home. Each prefilled syringe or autoinjector contains 162 mg of Actemra in 0.9 mL.
Your first injection is usually done under medical supervision to make sure you feel comfortable with the process. You will also be shown how to keep track of your dosing schedule and how to safely dispose of used syringes or pens in an FDA-approved sharps container.
Actemra IV vs. SC Efficacy
Some patients prefer SC injections because they offer more convenience for long-term treatment, but both options are equally effective.
Studies have shown that SC Actemra is non-inferior to IV dosing. For example, the SUMMACTA trial demonstrated that both SC and IV Actemra were equally effective in controlling rheumatoid arthritis (RA) in the long term.
Safety was also similar between the two groups. However, injection site reactions were more common with SC injections. Additionally, patients who switched from one form to another did just as well as those who remained on the same form.
Long-term follow-up confirmed sustained efficacy up to 97 weeks for both routes. This provides flexibility in choosing the route of administration based on your preference, access to infusion centers, and tolerance.
Actemra Dosing For Rheumatoid Arthritis
Tocilizumab, the active ingredient in Actemra, is the first medication formulated to target interleukin-6 (IL-6) and has shown effectiveness in treating rheumatoid arthritis (RA).
You may use Actemra alone or combine it with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) if you have moderate to severe RA and haven’t responded well to one or more DMARDs. However, Actemra should not be combined with other biologic DMARDs because of a higher risk of infections.
IV Infusion Dose
If you are starting on IV Actemra, the typical initial dose is 4 mg/kg, given through a 60-minute infusion every 4 weeks. Depending on how you respond, your doctor may increase the dose to 8 mg/kg every 4 weeks.
Be aware that Actemra can cause dose-related changes in lab results, such as elevated liver enzymes, low white blood cell counts (neutropenia), or low platelet counts (thrombocytopenia). If any of these occur, your dose may be lowered back to 4 mg/kg.
The maximum allowed per infusion is 800 mg.
Subcutaneous (SC) Dose
If you weigh less than 100 kg, you will likely start with a 162 mg SC injection every other week. If needed, this can be increased to every week based on how you respond. If you weigh 100 kg or more, you’ll begin with 162 mg every week.
If lab changes appear during treatment, your injection frequency may be reduced to every other week. You shouldn’t receive more than 162 mg weekly, as higher or more frequent doses haven’t been studied for safety or effectiveness.
Duration of Therapy
There isn’t a set time limit for treatment. You’ll likely continue using Actemra as long as it provides therapeutic benefits without causing serious side effects. Your doctor will check regularly to decide if you should keep using it.
Since biologics are more expensive than csDMARDs, experts have explored the possibility of increasing the interval between Actemra infusions while still aiming to reduce the risk of flare.
One study examined RA patients who had been in remission for at least 3 months and were getting Actemra infusions every 4 weeks. They first stretched out the infusions to every 6 weeks for 3 months. After that, doctors decided how much longer they could space out the infusions for each patient.
After two years, 8 patients remained on Actemra. Six of them managed to continue with longer intervals between treatments, and 4 could wait 8 weeks or more between infusions.
It seems possible for some RA patients to stretch out or lower their Actemra treatments once they are in remission, but bigger studies are needed to confirm if this is a safe long-term strategy.
Actemra Dosing For Giant Cell Arteritis (GCA)
Actemra is approved to treat GCA, a condition that causes inflammation in your large arteries. You will usually receive it along with corticosteroids to help bring the disease under control and to eventually reduce your steroid dose.
IV Infusion Dose
If you are receiving Actemra by IV infusion, the recommended dose for GCA is 6 mg/kg every 4 weeks. Each infusion takes about 60 minutes. You will continue taking a tapering course of glucocorticoids along with it. Doses higher than 600 mg per infusion are not recommended.
Since 6 mg/kg is the only approved IV dose for GCA, if you experience any dose-related lab changes, such as changes in your liver function or blood counts, your doctor may temporarily pause your treatment instead of lowering the dose.
Subcutaneous (SC) Dose
For SC injection, the typical starting dose is 162 mg once weekly, again combined with a tapering course of corticosteroids. In some situations, your doctor might change your dosing to every other week, such as:
-
- If you have trouble tolerating weekly injections
- If your disease remains in stable remission
- If you develop lab abnormalities related to the treatment
You should not receive more than 162 mg per week with SC dosing.
Duration of Therapy
The ideal treatment length for GCA is still uncertain.
Roche, the company that developed Actemra, suggests that up to one year of treatment could be enough to maintain remission long-term.
However, a study involving 336 GCA patients in England showed that about one-third of people relapsed within a year after stopping Actemra, and about half experienced a relapse within two years.
Another study suggests that tapering Actemra is better than stopping it abruptly if you want to stay in remission longer. Among patients who tapered their treatment to an injection every two weeks, 16% experienced a relapse within the first year. In a separate group of patients who tapered to every three weeks, only 11% experienced a relapse within the first year.
In comparison, among patients who stopped Actemra suddenly without tapering, 46% experienced a relapse within the first year.
If you have GCA and are planning to stop Actemra, your doctor will likely recommend tapering the dose gradually rather than stopping it all at once.
Actemra Dosing For Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Approved in March 2021, Actemra is the first biologic therapy approved to slow lung function decline in adults with SSc-ILD.
For SSc-ILD, Actemra is administered only as a subcutaneous injection using the prefilled syringe. Intravenous administration is not approved for this condition, and the ACTPen autoinjector has not been studied in SSc-ILD.
The recommended dose is 162 mg once every week. Interruption of dosing may be necessary if laboratory abnormalities occur.
Actemra is intended for long-term, continuous use as long as it provides clinical benefit and no serious safety concerns arise.
Actemra Dosing For Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Actemra is approved for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in children aged 2 years and older.
There are two types of polyarticular JIA based on blood tests:
-
- RF-positive: Affects five or more joints within the first six months. This type behaves more like adult rheumatoid arthritis and can be more severe and chronic.
-
- RF-negative: Also affects five or more joints but tends to be less aggressive.
Actemra may be used alone or with methotrexate when there is an inadequate response to conventional DMARDs.
IV Infusion Dose
If your child weighs less than 30 kg, the recommended dose is 10 mg/kg every 4 weeks. If the child weighs 30 kg or more, the dose is 8 mg/kg every 4 weeks. Each IV infusion is administered over a 60-minute period.
Subcutaneous (SC) Dose
If your child weighs less than 30 kg, the SC dose is 162 mg every 3 weeks. If they weigh 30 kg or more, it’s 162 mg every 2 weeks.
Similar to other indications, dose interruptions are recommended if lab abnormalities occur during therapy.
Duration of Therapy
PJIA often requires long-term therapy to control inflammation and prevent joint damage. Some pediatric patients may achieve remission after a year or more and attempt to taper off, while others may need ongoing treatment through adolescence.
Actemra Dosing For Systemic Juvenile Idiopathic Arthritis (SJIA)
Actemra is also approved for systemic JIA (SJIA) in patients aged 2 years and older. Unlike PJIA, SJIA is characterized by body-wide inflammation, often accompanied by daily fevers, rash, lymph node enlargement, and liver or spleen swelling.
For this indication, Actemra may be used alone or in combination with methotrexate.
IV Infusion Dose
Children weighing less than 30 kg receive 12 mg/kg every 2 weeks, while children weighing 30 kg or more receive 8 mg/kg every 2 weeks. Each infusion takes 60 minutes.
Subcutaneous (SC) Dose
Dosing for children weighing less than 30 kg is 162 mg every 2 weeks. For those who weigh 30 kg or more, the dose remains 162 mg, but is administered weekly. As with other conditions, dosing may be interrupted if lab abnormalities occur.
Duration of Therapy
Many patients with SJIA will require long-term therapy. Actemra helps control both arthritis symptoms and systemic features such as fever and rash. Some children may achieve remission after a year or more and attempt to taper off treatment. However, others may relapse and need continued therapy for several years through childhood.
Actemra Dosing For Cytokine Release Syndrome (CRS)
Actemra is approved for the treatment of severe or life-threatening cytokine release syndrome (CRS) in adults and children aged 2 years and older. CRS occurs when the immune system releases excessive cytokines, leading to symptoms such as:
-
- High fever
- Low blood pressure
- Breathing problems
- Organ damage, if severe
Notably, Actemra is only approved for CRS caused by CAR-T therapy, which is a type of immunotherapy used mainly to treat blood cancers like certain leukemias and lymphomas.
If you are receiving Actemra for CRS, it will be given to you through IV infusion. Actemra is not approved for subcutaneous injection in this situation. You will receive a single dose based on your body weight.
If you weigh less than 30 kg, you will receive 12 mg/kg of Actemra infused over 60 minutes. If you weigh 30 kg or more, you will receive 8 mg/kg. Note that your dose per infusion should not exceed 800 mg.
Unlike in other conditions, doctors usually do not adjust your Actemra dose if any lab abnormalities are detected during CRS treatment. This is because low blood counts and higher liver enzyme levels are common when you have CRS or after chemotherapy.
Your medical team will focus on treating the CRS as a life-threatening emergency, even if some lab results are abnormal.
Duration of Therapy
Actemra is used as a short-term treatment for CRS. You will only receive it during the CRS episode. Once your CRS improves, Actemra will be stopped. If you need CAR-T therapy again in the future and CRS happens again, your doctors may decide to use Actemra again.
If your CRS symptoms do not get better or if they worsen after the first dose, you may receive up to three additional doses. Each extra dose is given at least 8 hours after the previous one.
If there is still no improvement after two doses, your doctors will usually add other treatments, like corticosteroids, to help control the symptoms.
In rare cases where CRS stays severe even after Actemra and steroids, other medications such as etanercept (Enbrel) or infliximab (Remicade) might be considered as third-line options.
Actemra Dosing For Coronavirus Disease 2019 (COVID-19)
Actemra is approved for treating COVID-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or ECMO.
If you are receiving Actemra for COVID-19, it will be given to you by IV infusion only. Actemra is not approved as a subcutaneous injection for COVID-19 treatment. You will receive a dose of 8 mg/kg administered over a 60-minute IV infusion. Your dose should not go over 800 mg in a single infusion.
Like in CRS treatment, Actemra for COVID-19 is a short-term therapy. If your symptoms do not get better or if they worsen after the first dose, you may receive one more infusion at least 8 hours after the first one.
After that, you will no longer receive Actemra. Your COVID-19 care will go on with other treatments, such as steroids, antivirals if needed, and breathing support.
Summary of Actemra’s IV and SC Dosing
Here’s a table summarizing all the Actemra dosing guidelines across its FDA-approved uses:
| Formulation | Dosing | Frequency | Special Notes |
|---|---|---|---|
| Rheumatoid Arthritis (RA) | |||
| IV Infusion | 4 mg/kg (can increase to 8 mg/kg) | Every 4 weeks | Max 800 mg per infusion. Dose may be adjusted based on lab tests. |
| SC Injection | 162 mg |
|
|
| Giant Cell Arteritis (GCA) | |||
| IV Infusion | 6 mg/kg | Every 4 weeks | Max 600 mg per infusion. Used with steroid tapering. |
| SC Injection | 162 mg | Once a week | Some patients may switch to every other week if needed. |
| Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) | |||
| SC Injection using the prefilled syringe only | 162 mg | Once a week | IV infusion is not approved for SSc-ILD, and pen has not been studied. |
| Polyarticular Juvenile Idiopathic Arthritis (pJIA) | |||
| IV Infusion |
|
Every 4 weeks | |
| SC Injection | 162 mg |
|
|
| Systemic Juvenile Idiopathic Arthritis (sJIA) | |||
| IV Infusion |
|
Every 2 weeks | |
| SC Injection | 162 mg |
|
|
| Cytokine Release Syndrome (CRS) after CAR-T therapy | |||
| IV Infusion only |
|
One-time dose | May repeat up to 3 additional doses if needed (each at least 8 hours apart). Max 800 mg per dose. |
| COVID-19 (Hospitalized Adults) | |||
| IV Infusion only | 8 mg/kg | One-time dose | May repeat once after at least 8 hours if no improvement. Max 800 mg per dose. |
Transitioning Between Actemra Formulations
You can transition from IV to SC Actemra. Most patients often start on IV infusions and later switch to SC injections for convenience, especially if they are stable and doing well on treatment.
Here’s how it works, based on official guidelines:
-
- Timing: When switching from IV to SC, you simply take your first SC injection at the time your next IV dose would have been due. For example, if your IV Actemra was every 4 weeks, you would give the SC injection when the next IV would have happened. There should be no overlap, no extra loading dose needed, and no long delay.
-
- Dosing: After the switch, you follow the SC dosing schedule based on your condition.
Clinical studies, such as the SUMMACTA trial, have shown that switching between IV and SC forms of Actemra does not affect the drug’s efficacy and does not increase safety risks.
Bottom Line
Actemra can be given either through IV infusion or subcutaneous injection, with both options shown to be equally effective. SC injections are more convenient for long-term use, while IV infusions are preferred in hospital settings or emergencies like CRS and COVID-19.
The dose and frequency depend on your condition, weight, and how well you tolerate treatment. Some conditions, like RA and GCA, allow both IV and SC options, while others, like SSc-ILD and COVID-19, have specific approved routes. Pediatric dosing for PJIA and SJIA also follows strict weight-based schedules.
Transitioning between IV and SC is possible without losing treatment effectiveness. If you miss a dose, it’s important to follow instructions carefully to stay on track.
Frequently Asked Questions
Sources
Burmester, G. R., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D., Rangaraj, M. J., Roane, G., Ludivico, C., Bao, M., Rowell, L., Davies, C., & Mysler, E. F. (2015). Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Annals of the Rheumatic Diseases, 75(1), 68–74. https://doi.org/10.1136/annrheumdis-2015-207281
Ladhari, C., Blay, P. L., Vincent, T., Larbi, A., Rubenstein, E., Lopez, R. F., Jorgensen, C., & Pers, Y. (2020). Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study. BMC Rheumatology, 4(1). https://doi.org/10.1186/s41927-019-0109-0
Quick, V., Abusalameh, M., Ahmed, S., Alkoky, H., Bukhari, M., Carter, S., Coath, F. L., Davidson, B., Doddamani, P., Dubey, S., Ducker, G., Griffiths, B., Gullick, N., Heaney, J., Holloway, A., Htut, E. E. P., Hughes, M., Irvine, H., Kinder, A., . . . Mackie, S. L. (2023). Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England. Lara D. Veeken, 63(12), 3407–3414. https://doi.org/10.1093/rheumatology/kead604
Quick, V., Benson, F., & Mackie, S. L. (2024). Life after tocilizumab given for giant cell arteritis: a patient survey and argument for re-treatment. Rheumatology Advances in Practice, 8(2). https://doi.org/10.1093/rap/rkae054
Nielsen, M. K., Nielsen, A. W., Donskov, A. O., Hansen, I. T., Nielsen, B. D., Mørk, C., Hauge, E. M., & Keller, K. K. (2024). Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center. Seminars in Arthritis and Rheumatism, 68, 152508. https://doi.org/10.1016/j.semarthrit.2024.152508
GenenTech: Press Releases | Thursday, Mar 4, 2021. (2021, March 4). https://www.gene.com/media/press-releases/14897/2021-03-04/genentechs-actemra-becomes-the-first-bio
Canadian Agency for Drugs and Technologies in Health. (2024, May 1). Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-Cell engager or CAR T-Cell therapy. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK604827/
Actemra, Tofidence (tocilizumab) dosing, indications, interactions, adverse effects, and more. (n.d.). https://reference.medscape.com/drug/actemra-tofidence-tocilizumab-999419
